Literature DB >> 2157866

Identification of a glucocorticoid-responsive element in Epstein-Barr virus.

S R Kupfer1, W C Summers.   

Abstract

Immortalization of B lymphocytes by Epstein-Barr virus (EBV) is complex and poorly understood. However, some evidence suggests that glucocorticoids influence this process. We identified a glucocorticoid-responsive element in the BamHI C fragment of EBV which we call ES-1. In glucocorticoid-treated cells, ES-1 enhanced chloramphenicol acetyltransferase gene expression from the herpes simplex virus thymidine kinase promoter, as well as the EBV Bam-C promoter, from which several latent viral gene products are transcribed. By Northern blot analysis, glucocorticoid treatment enhanced transcription from the Bam-C promoter in Jijoye cells, a Burkitt's lymphoma cell line. In addition, the DNA-binding domain of the glucocorticoid receptor bound specifically to the ES-1 region. These glucocorticoid effects on the Bam-C promoter region may provide some insight into the process of EBV immortalization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157866      PMCID: PMC249352          DOI: 10.1128/JVI.64.5.1984-1990.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Enhancement of Epstein-Barr virus replication in producer cell lines by a combination of low temperature and corticosteroids.

Authors:  I T Magrath; P A Pizzo; L Novikovs; A S Levine
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements.

Authors:  B Luckow; G Schütz
Journal:  Nucleic Acids Res       Date:  1987-07-10       Impact factor: 16.971

3.  A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus.

Authors:  M Bodescot; M Perricaudet; P J Farrell
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

6.  Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus.

Authors:  M L Cleary; M A Nalesnik; W T Shearer; J Sklar
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

7.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

8.  Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.

Authors:  R J Murray; D Wang; L S Young; F Wang; M Rowe; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

9.  Many transcription factors interact synergistically with steroid receptors.

Authors:  R Schüle; M Muller; C Kaltschmidt; R Renkawitz
Journal:  Science       Date:  1988-12-09       Impact factor: 47.728

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  19 in total

1.  Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines.

Authors:  T Nilsson; H Zetterberg; Y C Wang; L Rymo
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression.

Authors:  A J Sinclair; M Brimmell; P J Farrell
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Social regulation of human gene expression: mechanisms and implications for public health.

Authors:  Steven W Cole
Journal:  Am J Public Health       Date:  2013-08-08       Impact factor: 9.308

4.  B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1.

Authors:  L I Yoo; M Mooney; M T Puglielli; S H Speck
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.

Authors:  E M Fuentes-Pananá; P D Ling
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 6.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

7.  Molecular genetic analysis of Epstein-Barr virus Cp promoter function.

Authors:  T J Evans; P J Farrell; S Swaminathan
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.

Authors:  N S Sung; J Wilson; M Davenport; N D Sista; J S Pagano
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

9.  Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).

Authors:  E M Fuentes-Pananá; S Swaminathan; P D Ling
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 10.  Nervous system regulation of the cancer genome.

Authors:  Steven W Cole
Journal:  Brain Behav Immun       Date:  2012-12-01       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.